<DOC>
	<DOCNO>NCT02270307</DOCNO>
	<brief_summary>Evaluating effectiveness new protocol replace standard immunosuppressive therapy use MSCs CY patient high risk relapse .</brief_summary>
	<brief_title>MSC Cyclophosphamide Acute Graft-Versus-Host Disease ( aGVHD ) Prophylaxis</brief_title>
	<detailed_description>This trial try find new way refractory hematological malignancy treatment . Aim study evaluate effectiveness new protocol replace standard immunosuppressive therapy use MSCs CY patient high risk relapse .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>Refractory form acute leukemia , complete remission ( CR ) Second third remission acute leukemia 2nd 3rd chronic phase chronic myelogenous leukemia ( CML ) ( Ph + ALL ) relapse multiple myeloma advance leukemia ICU Mechanical ventilation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>